HER2+  ||| S:0 E:6 ||| NNP
breast  ||| S:6 E:13 ||| NN
cancer ||| S:13 E:19 ||| NN
:  ||| S:19 E:21 ||| :
how  ||| S:21 E:25 ||| WRB
to  ||| S:25 E:28 ||| TO
evaluate ||| S:28 E:36 ||| VB
?  ||| S:36 E:38 ||| .
Approximately  ||| S:38 E:52 ||| RB
15 ||| S:52 E:54 ||| CD
% ||| S:54 E:55 ||| NN
-30 ||| S:55 E:58 ||| CD
%  ||| S:58 E:60 ||| NN
of  ||| S:60 E:63 ||| IN
breast  ||| S:63 E:70 ||| JJ
cancers  ||| S:70 E:78 ||| NNS
have  ||| S:78 E:83 ||| VBP
overexpression  ||| S:83 E:98 ||| VBN
or  ||| S:98 E:101 ||| CC
amplification  ||| S:101 E:115 ||| NN
of  ||| S:115 E:118 ||| IN
human  ||| S:118 E:124 ||| JJ
epidermal  ||| S:124 E:134 ||| JJ
growth  ||| S:134 E:141 ||| NN
factor  ||| S:141 E:148 ||| NN
receptor  ||| S:148 E:157 ||| NN
2  ||| S:157 E:159 ||| CD
( ||| S:159 E:160 ||| -LRB-
HER2 ||| S:160 E:164 ||| NNP
) ||| S:164 E:165 ||| -RRB-
,  ||| S:165 E:167 ||| ,
which  ||| S:167 E:173 ||| WDT
is  ||| S:173 E:176 ||| VBZ
associated  ||| S:176 E:187 ||| VBN
with  ||| S:187 E:192 ||| IN
a  ||| S:192 E:194 ||| DT
worse  ||| S:194 E:200 ||| JJR
prognosis  ||| S:200 E:210 ||| NN
in  ||| S:210 E:213 ||| IN
the  ||| S:213 E:217 ||| DT
absence  ||| S:217 E:225 ||| NN
of  ||| S:225 E:228 ||| IN
therapy ||| S:228 E:235 ||| NN
.  ||| S:235 E:237 ||| .
While  ||| S:237 E:243 ||| IN
HER2  ||| S:243 E:248 ||| CD
testing  ||| S:248 E:256 ||| NN
is  ||| S:256 E:259 ||| VBZ
common  ||| S:259 E:266 ||| JJ
there  ||| S:266 E:272 ||| EX
are  ||| S:272 E:276 ||| VBP
issues  ||| S:276 E:283 ||| NNS
associated  ||| S:283 E:294 ||| VBN
with  ||| S:294 E:299 ||| IN
its  ||| S:299 E:303 ||| PRP$
sensitivity  ||| S:303 E:315 ||| NN
and  ||| S:315 E:319 ||| CC
specificity ||| S:319 E:330 ||| NN
,  ||| S:330 E:332 ||| ,
which  ||| S:332 E:338 ||| WDT
may  ||| S:338 E:342 ||| MD
impact  ||| S:342 E:349 ||| VB
the  ||| S:349 E:353 ||| DT
perceived  ||| S:353 E:363 ||| JJ
usefulness  ||| S:363 E:374 ||| NN
of  ||| S:374 E:377 ||| IN
treatments ||| S:377 E:387 ||| NNS
.  ||| S:387 E:389 ||| .
The  ||| S:389 E:393 ||| DT
objectives  ||| S:393 E:404 ||| NNS
of  ||| S:404 E:407 ||| IN
this  ||| S:407 E:412 ||| DT
review  ||| S:412 E:419 ||| NN
are  ||| S:419 E:423 ||| VBP
to  ||| S:423 E:426 ||| TO
understand  ||| S:426 E:437 ||| VB
the  ||| S:437 E:441 ||| DT
characteristics  ||| S:441 E:457 ||| NNS
and  ||| S:457 E:461 ||| CC
peculiarities  ||| S:461 E:475 ||| NNS
of  ||| S:475 E:478 ||| IN
HER2+  ||| S:478 E:484 ||| CD
breast  ||| S:484 E:491 ||| NN
cancer ||| S:491 E:497 ||| NN
,  ||| S:497 E:499 ||| ,
and  ||| S:499 E:503 ||| CC
to  ||| S:503 E:506 ||| TO
discuss  ||| S:506 E:514 ||| VB
the  ||| S:514 E:518 ||| DT
issues  ||| S:518 E:525 ||| NNS
associated  ||| S:525 E:536 ||| VBN
with  ||| S:536 E:541 ||| IN
the  ||| S:541 E:545 ||| DT
correlation  ||| S:545 E:557 ||| NN
of  ||| S:557 E:560 ||| IN
HER2  ||| S:560 E:565 ||| CD
immunogenicity  ||| S:565 E:580 ||| NN
with  ||| S:580 E:585 ||| IN
therapeutic  ||| S:585 E:597 ||| JJ
response ||| S:597 E:605 ||| NN
,  ||| S:605 E:607 ||| ,
especially  ||| S:607 E:618 ||| RB
of  ||| S:618 E:621 ||| IN
trastuzumab ||| S:621 E:632 ||| NN
.  ||| S:632 E:634 ||| .
There  ||| S:634 E:640 ||| EX
are  ||| S:640 E:644 ||| VBP
two  ||| S:644 E:648 ||| CD
issues  ||| S:648 E:655 ||| NNS
associated  ||| S:655 E:666 ||| VBN
with  ||| S:666 E:671 ||| IN
the  ||| S:671 E:675 ||| DT
correlation  ||| S:675 E:687 ||| NN
between  ||| S:687 E:695 ||| IN
HER2  ||| S:695 E:700 ||| CD
immunogenicity  ||| S:700 E:715 ||| NNS
and  ||| S:715 E:719 ||| CC
therapeutic  ||| S:719 E:731 ||| JJ
response ||| S:731 E:739 ||| NN
:  ||| S:739 E:741 ||| :
possible  ||| S:741 E:750 ||| JJ
resistance  ||| S:750 E:761 ||| NN
to  ||| S:761 E:764 ||| TO
trastuzumab  ||| S:764 E:776 ||| VB
through  ||| S:776 E:784 ||| IN
lack  ||| S:784 E:789 ||| NN
of  ||| S:789 E:792 ||| IN
phosphatase  ||| S:792 E:804 ||| NN
and  ||| S:804 E:808 ||| CC
tensin  ||| S:808 E:815 ||| JJ
analog  ||| S:815 E:822 ||| NN
or  ||| S:822 E:825 ||| CC
receptor  ||| S:825 E:834 ||| JJ
expression ||| S:834 E:844 ||| NN
,  ||| S:844 E:846 ||| ,
and  ||| S:846 E:850 ||| CC
nonspecific  ||| S:850 E:862 ||| NNS
or  ||| S:862 E:865 ||| CC
insensitive  ||| S:865 E:877 ||| JJ
measurement  ||| S:877 E:889 ||| NN
of  ||| S:889 E:892 ||| IN
HER2  ||| S:892 E:897 ||| CD
expression ||| S:897 E:907 ||| NN
.  ||| S:907 E:909 ||| .
These  ||| S:909 E:915 ||| DT
issues  ||| S:915 E:922 ||| NNS
can  ||| S:922 E:926 ||| MD
be  ||| S:926 E:929 ||| VB
addressed  ||| S:929 E:939 ||| VBN
through  ||| S:939 E:947 ||| IN
the  ||| S:947 E:951 ||| DT
evaluation  ||| S:951 E:962 ||| NN
of  ||| S:962 E:965 ||| IN
other  ||| S:965 E:971 ||| JJ
factors  ||| S:971 E:979 ||| NNS
in  ||| S:979 E:982 ||| IN
addition  ||| S:982 E:991 ||| NN
to  ||| S:991 E:994 ||| TO
HER2  ||| S:994 E:999 ||| CD
status  ||| S:999 E:1006 ||| NN
at  ||| S:1006 E:1009 ||| IN
diagnosis ||| S:1009 E:1018 ||| NN
,  ||| S:1018 E:1020 ||| ,
and  ||| S:1020 E:1024 ||| CC
improvements  ||| S:1024 E:1037 ||| NNS
in  ||| S:1037 E:1040 ||| IN
the  ||| S:1040 E:1044 ||| DT
performance  ||| S:1044 E:1056 ||| NN
and  ||| S:1056 E:1060 ||| CC
validation  ||| S:1060 E:1071 ||| NN
of  ||| S:1071 E:1074 ||| IN
HER2  ||| S:1074 E:1079 ||| CD
testing ||| S:1079 E:1086 ||| NN
.  ||| S:1086 E:1088 ||| .
It  ||| S:1088 E:1091 ||| PRP
is  ||| S:1091 E:1094 ||| VBZ
important  ||| S:1094 E:1104 ||| JJ
that  ||| S:1104 E:1109 ||| IN
HER2  ||| S:1109 E:1114 ||| CD
tests  ||| S:1114 E:1120 ||| NNS
are  ||| S:1120 E:1124 ||| VBP
of  ||| S:1124 E:1127 ||| IN
the  ||| S:1127 E:1131 ||| DT
highest  ||| S:1131 E:1139 ||| JJS
quality  ||| S:1139 E:1147 ||| NN
and  ||| S:1147 E:1151 ||| CC
that  ||| S:1151 E:1156 ||| IN
laboratories  ||| S:1156 E:1169 ||| NNS
performing  ||| S:1169 E:1180 ||| VBG
the  ||| S:1180 E:1184 ||| DT
tests  ||| S:1184 E:1190 ||| NNS
are  ||| S:1190 E:1194 ||| VBP
assessed  ||| S:1194 E:1203 ||| VBN
and  ||| S:1203 E:1207 ||| CC
validated  ||| S:1207 E:1217 ||| JJ
correctly ||| S:1217 E:1226 ||| NN
.  ||| S:1226 E:1228 ||| .
Pathologists  ||| S:1228 E:1241 ||| NNP
must  ||| S:1241 E:1246 ||| MD
proactively  ||| S:1246 E:1258 ||| RB
monitor  ||| S:1258 E:1266 ||| VB
the  ||| S:1266 E:1270 ||| DT
quality  ||| S:1270 E:1278 ||| NN
of  ||| S:1278 E:1281 ||| IN
their  ||| S:1281 E:1287 ||| PRP$
tests  ||| S:1287 E:1293 ||| NNS
and  ||| S:1293 E:1297 ||| CC
oncologists  ||| S:1297 E:1309 ||| NNS
should  ||| S:1309 E:1316 ||| MD
ensure  ||| S:1316 E:1323 ||| VB
that  ||| S:1323 E:1328 ||| IN
all  ||| S:1328 E:1332 ||| DT
breast  ||| S:1332 E:1339 ||| NN
cancer  ||| S:1339 E:1346 ||| NN
cases  ||| S:1346 E:1352 ||| NNS
are  ||| S:1352 E:1356 ||| VBP
assessed  ||| S:1356 E:1365 ||| VBN
for  ||| S:1365 E:1369 ||| IN
HER2 ||| S:1369 E:1373 ||| NNP
,  ||| S:1373 E:1375 ||| ,
as  ||| S:1375 E:1378 ||| RB
only  ||| S:1378 E:1383 ||| RB
then  ||| S:1383 E:1388 ||| RB
can  ||| S:1388 E:1392 ||| MD
the  ||| S:1392 E:1396 ||| DT
patients  ||| S:1396 E:1405 ||| NNS
benefit  ||| S:1405 E:1413 ||| VBP
from  ||| S:1413 E:1418 ||| IN
specific  ||| S:1418 E:1427 ||| JJ
and  ||| S:1427 E:1431 ||| CC
appropriate  ||| S:1431 E:1443 ||| JJ
therapy ||| S:1443 E:1450 ||| NN
.  ||| S:1450 E:1452 ||| .
